Thus, the authors provided the evidence that by modulating the glutamatergic transmission using known inhibitors or experimental KYNA derivatives, the overexpression of PACAP, as a valid biomarker of migraine, would be prevented. The gene discussed is ADCYAP1; the disease is migraine disorder.